Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Bulletin of Alexandria Faculty of Medicine. 2008; 44 (4): 729-734
em Inglês | IMEMR | ID: emr-99555

RESUMO

In the past, pseudomyxoma peritonei was considered an incurable disease and often no active treatment was given. With the advent of cyto-reductive surgery, including peritonectomy procedures and intra peritoneal chemotherapy, long-term survival of these patients became actually possible. To study the impact of the intraperitoneal hyperthermic chemotherapy [cisplatin], when locally administered in patients who presented with pseudomyxoma peritonei and were treated by extensive cyto-reductive surgery. Nine patients with and. peritoneal adenomucinosis or carcinomatosis arising from the appendix who presented with a clinical picture of pseudomyxoma peritonei were diagnosed, and treated by cyto-reductive surgery followed by 6 cycles of ultrasound-guided intraperitoneal hyperthermic cisplatin. Following aggressive surgical approach and intraperitoneal chemotherapy, 7 patients had 1 year disease free survival, achieved independent activity in daily living and had an improved quality of life. The other 2 patients developed recurrences at 8 and 10 months following the completion of treatment. No major [grade III] texicities were observed. Pseudomyxoma peritonei is a treatable condition that may result in long-term disease free survival. Successful management can be achieved by combining cyto-reductive surgery and intraperitoneal hyperthermic chemotherapy


Assuntos
Humanos , Masculino , Feminino , Injeções Intraperitoneais/métodos , Ultrassonografia , Cisplatino , Procedimentos Cirúrgicos Operatórios , Taxa de Sobrevida , Antígeno Carcinoembrionário , Tomografia Computadorizada por Raios X/métodos , Metástase Neoplásica , Biópsia , Patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA